# QUICK GUIDE FOR PEDIATRIC EMERGENCIES

Dr. Venugopal Reddy Iragamreddy et.al



Medical and Research Publications

# QUICK GUIDE FOR PEDIATRIC EMERGENCIES Written by

Author

### Dr. Venugopal Reddy Iragamreddy

Medical Director and Consultant Paeditrician, OVUM Hospital, Bangalore, India.

Co-Author

### Dr Chethan C S

consultant paediatrician and lead paediatric intensivist in Ovum Women and Child Hospitals, India.

### **QUICK GUIDE FOR PEDIATRIC EMERGENCIES**

### Medical and Research Publications

Copyright © 2023 Dr. Dr. Venugopal Reddy Iragamreddy et.al

All rights reserved. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the express written permission of the publisher except for the use of brief quotations in a book review..

First printing, 2023. ISBN: 978-81-958535-5-7

Published by Medical and Research Publications, 124SpencerRd,Stoke-on-TrentST42BE, United Kingdom.

www.medicalandresearch.com Email: info@medicalandresearch.com

## Index:

Content	Page no.
1. PEDIATRIC EQUIPMENT	1
2. ACUTE EXACERBATION OF ASTHMA	2-3
3. ANAPHYLAXIS	4-5
4. BARBITURATE POISONING	6-7
5. BRONCHIOLITIS	8 - 10
6. CAMPHOR POISONING	11-12
7. CORROSIVE POISONING	13-15
8. CROUP	16-18
9. CYANOTIC SPELL	19-20
10. DIABETIC KETOACIDOSIS	21-23
11. DIARRHEA WITH DEHYDRATION	24-25
12. DISC BATTERY INGESTION	26-27
13.GENERAL APPROACH TO A CHILD WITH POISONING	28-32
14. HYPERTENSIVE CRISIS IN CHILDREN	33-35
15. IRON POISONING	36-37
16.KEROSENE POISONING	38-39
17. NAPHTHALENE POISONING	40-41
18. ORGANOPHOSPHATES POISONING	42-43
<b>19. OPIATE TOXICITY</b>	44-45
20. PARACETAMOL TOXICITY	46-48
21. POLYTRAUMA	49-51
22. PYRETHRIN & PYRETHROID POISONING	52-53
23. RODENTICIDE POISONING	54
24. SALICYLATE POISONING	55-56

25. SCORPION STING – MANAGEMENT	57
26. SEPTIC SHOCK	59-60
27. SNAKE ENVENOMATION	61-62
28. STATUS EPILEPTICS	63-64
29. TRICYCLIC ANTIDEPRESSANTS POISONING	65-66
<b>30. TRAUMATIC BRAIN INJURY (TBI)</b>	67-69
31.BIBLIOGRAPHY	70-73



## PEDIATRIC EQUIPMENT

	Newborn	6	1 yrs	2-3	4-6	7-	11-	>16
		months		yrs	yrs	10yrs	15yrs	yrs
Weight	2-4	6-8	10	12-	20-	25-35	40-50	>50
				16	25			
Laryngoscope	MIL 0	MIL 1	MIL	MIL	MIL	MIL	MIL	MIL
Blade			1	1	2	2	2	2
			MAC	MAC	MAC	MAC	MAC	MAC
			2	2	2	2	3	3
Endo	3.0-3.5	3.5	4.0	4.0-	4.5-	5.5-	6.0-	7.0-
tracheal tube				4.5	5.0	6.0	6.5	8.0
Laryngeal	1	1.5	2	2	2.5	2.5-3	3	4
mask airway								
Central	3-4	4	4-5	4-5	5	5	7	7
venous line								
(Fr)								
NG Tube (Fr)	5-8	8	10	10-	12-	12-14	14-18	14-
				12	14			18
Chest tube	10-12	12-18	16-	16-	20-	20-32	28-38	28-
(Fr)			20	24	28			42
Foley (Fr)	8	8	8	8	8	8	10	12
		ENDOTRA	CHEAL TU	BE(ETT) FO	RMULAS			
		Uncuff	ed ETT size	= Age(years)/	4 + 4			
		cuffed	ETT size = $A$	Age(years)/4 -	+ 3.5			
	ETT de	epth (from lip to	mid-trachea	): ETT interna	al diameter (s	ize) x 3		



### CHAPTER-1 ACUTE EXACERBATION OF ASTHMA

Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms, such as wheeze, shortness of breath, chest tightness and cough, that vary over time and in intensity, together with variable expiratory airflow limitation.<sup>1</sup>

Exacerbations of asthma are episodes characterized by a progressive increase in symptoms of shortness of breath, cough, wheezing or chest tightness and progressive decrease in lung function, i.e., they represent a change from the patient's usual status that is sufficient to require a change in treatment.<sup>2</sup>


Management in an emergency depends on the severity at presentation and response to treatment.

Symptom	Mild	Moderate	Severe or life threatening
Confused/drowsy	No	No	Agitated or altered
Oximetry on presentation (SpO2)	94%	94%-90%	Less that 90%
Talks in	Sentences	Phrases	Words or unable to speak
Pulse in	< 100 /min	100-200 /min	>200 /min or bradycardia
Central cyanosis	Absent	Absent	Likely to be present
Wheeze intensity	Variable, mainly at end exhalation	Moderate to loud, present in both phrases of respiration	Audible wheeze or silent chest due to poor air entry

#### Initial assessment of acute exacerbation of asthma:<sup>4</sup>



#### Initial management of children who have acute asthma.<sup>3</sup>





## CHAPTER-2 ANAPHYLAXIS

Anaphylaxis is an acute, potentially lethal, multisystem syndrome resulting from the sudden release of mast cell- and basophil-derived mediators into the circulation<sup>5</sup>.

It most often results from immunologic reactions to foods, medications, and insect stings, although it can also be induced through nonimmunologic mechanisms by any agent capable of producing a sudden, systemic degranulation of mast cells or basophils<sup>6</sup>.

#### CLINICAL CRITERIA FOR DIAGNOSING ANAPHYLAXIS<sup>5</sup>

Anaphylaxis is highly likely when any one of the following 3 criteria are fulfilled:
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue,
or both (e.g., generalized hives, pruritus or
flushing, swollen lips-tongue-uvula)
AND AT LEAST ONE OF THE FOLLOWING
a. Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory
flow, hypoxemia)
b. Reduced Blood Pressure or associated symptoms of end-organ dysfunction (e.g., hypotonia
[collapse], syncope, incontinence)
2. Two or more of the following that occur rapidly after exposure to a likely allergen for that patient
(minutes to several hours):
a. Involvement of the skin-mucosal tissue (e.g., generalized hives, itch-flush, swollen lips-tongue-
uvula)
b. Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced Peak
Expiratory Flow, hypoxemia)
c. Reduced Blood Pressure or associated symptoms (e.g., hypotonia [collapse], syncope,
incontinence)
d. Persistent gastrointestinal symptoms (e.g., crampy abdominal pain, vomiting)
3. Reduced Blood Pressure after exposure to known allergen for that patient (minutes to several
hours):
a. Infants and children: low systolic Blood Pressure (age specific) or greater than 30% decrease in
systolic Blood Pressure*
b. Adults: systolic Blood Pressure of less than 90 mm Hg or greater than 30% decrease from that
person's baseline



#### MANAGEMENT<sup>7</sup>:

Place patient in recumbent position

Airway: Immediate intubation if evidence of impending airway obstruction from angioedema. Delay may lead to complete obstruction.

Oxygen: Give 8 to 10 L/minute via facemask or up to 100% oxygen, as needed.

#### **Epinephrine:**

• The first and most important therapy in anaphylaxis is epinephrine. There are NO absolute contraindications to epinephrine in the setting of anaphylaxis.

• Epinephrine 0.01 mg/kg should be injected IM in the mid-outer thigh (maximum is 0.5 mg per dose)

• If there is no response or the response is inadequate, the injection can be repeated in 5 to 15 minutes (or more frequently). If epinephrine is injected promptly IM, patients respond to 1, 2, or, at most, 3 injections.

• If signs of poor perfusion are present or symptoms are not responding to epinephrine injections, prepare IV epinephrine for infusion 0.1 to 1.0mcg/kg/min

Normal saline rapid bolus: Treat poor perfusion with rapid infusion of 20 mL/kg. Reevaluate and repeat fluid boluses (20 mL/kg), as needed.

**Salbutamol:** For bronchospasm resistant to IM epinephrine, give Salbutamol 0.15 mg/kg (minimum dose: 2.5 mg) inhaled via nebulizer.

**H1 antihistamine:** Consider giving diphenhydramine 1 mg/kg (max 50 mg IV, over 5 minutes) or cetirizine (children aged 6 months to 5 years can receive 2.5 mg IV, those 6 to 11 years of age can receive 5 or 10 mg IV, over 2 minutes).

H2 antihistamine: consider giving IV ranitidine 1mg/kg/dose (max dose 50mg)

Glucocorticoid: Consider giving methylprednisolone 1 mg/kg (max 125 mg) IV.

Patient needs to be admitted and further managed in the ICU.

#### **Pediatric Pearls**

Stock adequate adrenaline & check expiry date every month

Observe patient for half an hour after administration of both vaccines & drugs routinely. Identify anaphylaxis prone children and teach parents to administer adrenaline in emergency situations.

EpiPen is an alternative but not available in India.



### CHAPTER-3 BARBITURATE POISONING

Barbiturates are a class of sedative-hypnotic drugs. They are commonly used as antiepileptics (phenobarbital) and for the induction of general anesthesia (thiopental).

#### Signs and Symptoms<sup>8</sup>:

Decreased level of consciousness Poor coordination Vertigo Nausea Muscle weakness Thirst Oliguria Decreased temperature Dilated or contracted pupils Bradycardia Rapid and weak pulse Fatal cases are marked by coma, hypotension and respiratory depression.

#### Investigations<sup>8</sup>:

Qualitative assessment of the amount of drug taken with a plasma or urine screening test. Plasma barbiturate concentration and ingested dose have been implicated as the most important correlates of toxicity.

Blood glucose, pH, and serum electrolytes

#### Management<sup>8,9,10</sup>:

Assessing the patient's airway, breathing, and circulation. With significant sedation and respiratory depression, intubation and mechanical ventilation may become necessary. Monitor and support Circulation by fluids, inotropes.



Gastric decontamination – Up to 6 hours post ingestion Ensure airway is adequately protected. Activated charcoal 1g/kg. Multiple doses may be required, repeated q4-6hrly x 4-6 times.

#### Forced alkaline diuresis.

Administer NaHCO3 (D5 with 80-150 meq/L of NaHO3 and KCI 20meq/L) to maintain Urine pH 7.5-8. It is important to avoid hypokalemia when we maintain an alkaline urine pH Ensure urine output of at least 2ml/kg/hr Monitor for and treat dyselectrolytemia

#### **Extracorporeal therapy (ECTR):**

The use of ECTR should be restricted to cases of severe long-acting barbiturate poisoning. The indications for ECTR in this setting are the presence of prolonged coma, respiratory depression necessitating mechanical ventilation, shock, persistent toxicity, or increasing or persistently elevated serum barbiturate concentrations despite treatment with multiple-dose activated charcoal.

Intermittent hemodialysis is the preferred mode of ECTR, and multiple-dose activated charcoal treatment should be continued during ECTR

Cessation of ECTR is indicated when clinical improvement is apparent.



## CHAPTER-4 BRONCHIOLITIS

Bronchiolitis is a clinical diagnosis, recognized as "a constellation of clinical symptoms and signs including a viral upper respiratory prodrome followed by increased respiratory effort and wheezing in children less than 2 years of age<sup>11</sup>.

#### Diagnosis<sup>12,13</sup>:

Diagnosis is based on clinical assessment. Lower respiratory tract symptoms and signs (cough, tachypnea, crepitations and wheezing) follow a viral prodromal phase (coryza/low grade fever)
 Do not routinely perform a chest X-ray in babies or children with bronchiolitis, because changes on X-ray may mimic pneumonia and should not be used to determine the need for antibiotics.

 $\hfill\square$  Indications for chest X- ray:

If respiratory distress is severe needing an ICU care Course is atypical

There is uncertainty about the diagnosis

□ Measure oxygen saturation in every baby and child presenting with suspected bronchiolitis

□ Do not routinely carry out blood gas testing in babies or children with bronchiolitis. Consider carrying out capillary blood gas testing in babies and children with severe worsening respiratory distress.

#### Differential diagnosis<sup>14</sup>:

Consider a diagnosis of pneumonia if the baby or child has:

- High fever (over 39°C) and/or
- Persistently focal crackles.

Consider diagnosis of viral-induced wheeze or early-onset asthma rather than bronchiolitis in older infants and young children if they have:

- Persistent wheeze without crackles or
- Recurrent episodic wheeze or
- Personal or family history of atopy.



#### Management<sup>12,13</sup>:

Adequate hydration:

Give fluids by nasogastric or orogastric tube in babies and children with

bronchiolitis if they cannot take enough fluid by mouth.

Give intravenous isotonic fluids (see the NICE guideline on intravenous

fluid therapy in children) to babies and children who:

• Do not tolerate nasogastric or orogastric fluids or

• Have impending respiratory failure.

Oxygen supplementation to babies and children with bronchiolitis if their oxygen saturation is:

• Persistently less than 90%, for children aged 6 weeks and over

• Persistently less than 92%, for babies under 6 weeks or children of any age with underlying health conditions.

□ Consider continuous positive airway pressure (CPAP) in babies and children with bronchiolitis who have impending respiratory failure.

□ High-flow nasal cannula (HFNC) oxygen may have a role as a rescue therapy to reduce proportion of those requiring intensive care.

**Upper airway suctioning** to be performed in children who have respiratory distress or feeding difficulties because of upper airway secretions or apnea.

**Do not use** any of the following to treat bronchiolitis in babies or children:

- Chest physiotherapy
- Antibiotics
- Hypertonic saline
- Adrenaline (nebulized)
- Salbutamol
- Montelukast
- Ipratropium bromide
- Systemic or inhaled corticosteroids
- A combination of systemic corticosteroids and nebulized adrenaline.
- Steam inhalation

• RSV polyclonal immunoglobulin/palivizumab (no role in acute management but useful in prophylaxis)



#### Indications for admission<sup>13</sup>:

- A respiratory rate of over 60 breaths/minute
- Difficulty with breastfeeding or inadequate oral fluid intake (50% to 75% of usual volume, taking account of risk factors and using clinical judgement)
- Clinical dehydration
- Persistent oxygen saturation of less than 92%, when breathing air

• Consider ICU admission in case of apnea (observed or reported), sick looking child, severe respiratory distress (grunting, marked chest recession, or a respiratory rate of over 70 breaths/minute) and central cyanosis.



### CHAPTER-5 CAMPHOR POISONING

Source<sup>14</sup>:

It is commonly seen in household items, including vaporized or topical cold preparations (for example Vicks Vaporub is 4.18% camphor and Tiger Balm), topical musculoskeletal anesthetics preparations (liniments), moth repellents, for performing rituals in religious ceremonies, and in antimicrobial preparations.

Camphor is also used in the Indian household in the form of small cubes for its fragrance.

Toxicity<sup>14,15</sup>:

 $\Box$  Major systemic toxicity has not been reported with ingestion of up to 30 mg/kg of camphor.

 $\Box$  The neurotoxic dose of camphor is 50 mg/kg body weight.

 $\Box$  The fatal dose is 500 mg/kg body weight.

 $\hfill\square$  Camphor is a rapidly acting neurotoxin and can lead to excitation followed by depression of

CNS. It is rapidly absorbed from GIT, leading to the rapid onset of action of toxic effects within

5-20 minutes, and peak effect occurs at 90 minutes.

 $\Box$  Seizures can occur after gastrointestinal, dermal, or inhalation exposures to camphor.

Clinical Presentation<sup>14,16</sup>:

 $\hfill\square$  There may be a strong smell from the breath.

□ Generalized warmth which progresses to burning sensation in pharynx and epigastrium and vomiting.

□ Changes in mental status (confusion, restlessness, delirium, and hallucinations)

□ Muscle twitching

 $\Box$  Myoclonus

- 🗆 Ataxia
- □ Hyperreflexia
- $\Box$  Fasciculations
- □ Seizures (most common reported symptom)

Management 1,2,3:

□ Support of Airway, Breathing and Circulation.



□ Skin and ocular decontamination should be done by flushing with large amount of water.

□ As camphor is rapidly absorbed from the stomach, gastric lavage and activated charcoal have a limited role in the management of camphor ingestion.

□ Seizures should be managed with benzodiazepines (midazolam and lorazepam) and repeat doses may be needed. For uncontrolled seizures, a second anticonvulsant is needed, such as phenobarbitone or phenytoin.

□Hemodialysis is not of much benefit.



## CHAPTER-6 CORROSIVE POISONING

Caustic ingestions are seen most often in young children between one and three years of age and can cause severe acute injury and long-term complications, especially the development of esophageal strictures.

Accidental ingestion is common in younger children (< 5 years) while suicidal ingestion is more common in adolescents.

#### Source:

Toilet bowl cleaners, metal cleaners, bleach, drain cleaners, paint removers, hair straightener, car batteries, rust removers, laundry detergents, dish washer detergents.

#### PATHOPHYSIOLOGY<sup>17</sup>:

Alkali		Acids	
~	Alkaline agents tend to cause esophageal injury if the pH is above 11.5 to 12.5 via liquefaction necrosis. This type of injury leads to early		Acids or corrosive agents tend to cause esophageal injury if the pH is less than 2, via coagulation necrosis. Esophageal injury from acids tend
	disintegration of the mucosa, allowing deep penetration and even perforation		to be attenuated and perforation is less common because the coagulum that forms on the mucosal surface may limit deeper penetration of the caustic substance

#### CLINICAL MANIFESTATIONS<sup>17</sup>:

Gastrointestinal tract injury	<ul> <li>✓ The most common symptom is dysphagia</li> <li>✓ Patients may also present with drooling, retrosternal or abdominal pain, and hematemesis.</li> <li>✓ Deep esophageal burns can be complicated by esophageal perforation, which can cause mediastinitis and the development of a tracheoesophageal fistula</li> </ul>
Upper airway injury	<ul> <li>Symptoms suggesting upper airway injury include stridor, hoarseness, nasal flaring, and retractions.</li> </ul>



#### **Evaluation:**

History and examination: History should seek to establish the timing of the exposure, including whether it was directly observed by a caretaker, and an estimation of the amount of the substance ingested.

#### Imaging


 $\Box$  A chest radiograph is appropriate in any patient with respiratory symptoms.

□ Computed tomography (CT) or magnetic resonance angiography are sometimes needed to evaluate patients for the possibility of esophageal perforation with erosion into vascular structures, including an aorto-esophageal fistula.

#### Management<sup>17,18</sup>:

□ The initial step in management of caustic ingestion is supportive care and close observation, with an emphasis on preventing vomiting, choking, and aspiration.

□ Gastric decontamination – lavage, activated charcoal are contraindicated





### Zargar classification for corrosive esophageal injury<sup>17,18</sup>

Injury	Findings	Management		
Grade 0 Grade 1 (superficial) Grade 2 (transmucosal)	Normal mucosa         Mucosal edema and         hyperemia         Friability, hemorrhages,         erosions, blisters, whitish         membranes, and         superficial ulcerations	<ul> <li>✓ Feed as tolerated</li> <li>✓ PPI for 1 week if s</li> <li>✓ UGI series in 2 to develops or for grade</li> </ul>	3 weeks if dysphagia	
Grade 2A	No deep focal or circumferential ulcers	_		
Grade 2B	Deep focal or circumferential ulcers	<ul> <li>✓ Place NG tube during endoscopy</li> <li>✓ Corticosteroids 3 days course</li> </ul>	<ul> <li>✓ PPI for one week</li> <li>✓ Antibiotics for 1 week</li> <li>✓ UGI series on 2 to 3 weeks or if</li> </ul>	
Grade 3	Areas of multiple ulceration and areas of brown-black or greyish discoloration suggesting necrosis	<ul> <li>✓ Place NG tube during endoscopy or consider gastrostomy</li> <li>✓ No corticosteroids</li> </ul>	dysphagia develops any time ✓ Dilatation as needed if esophageal strictures	
Grade 3A	Small scattered areas of focal necrosis		develop	
Grade 3B	Extensive necrosis			

UGI: upper gastrointestinal

PPI: proton pump inhibitors

NG: Nasogastric



### CHAPTER-7 CROUP

Viral croup is an age-specific viral syndrome characterized by laryngeal and subglottic edema that

primarily affects infants and children between 6 months and 3 years of age.<sup>19</sup>

The 3 hallmark signs of croup are hoarseness, cough, and stridor.<sup>19</sup>

Parainfluenza types 1, 2, and 3 are the most common viruses causing croup.<sup>19</sup>

#### **Diagnosis**<sup>20,21</sup>:

It is based on clinical assessment. Low grade fever, barking cough, variable degrees of stridor and respiratory distress are the common presenting manifestations.

Viral cultures and rapid antigen testing should be reserved for patients in whom initial treatment is ineffective.<sup>22</sup>

X- ray of neck/chest is not needed unless there is doubt about the diagnosis.

#### Westley Croup Score<sup>20</sup>

Clinical feature	Assigned score			
Level of consciousness				
Normal, including sleep	0			
Disoriented	5			
Cyanosis				
None	0			
With agitation	4			
At rest	5			
Stridor				
None	0			
With agitation	1			
At rest	2			
Air entry				
Normal	0			
Decreased	1			
Markedly decreased	2			
Retractions				
None	0			
mild	1			
moderate	2			
severe	3			
Total				



Differential Diagnosis<sup>20</sup>

Bacterial Tracheitis

Retropharyngeal/Para pharyngeal abscess

Epiglottitis

Foreign body

### Management<sup>20,22</sup>:

Score total	Severity	Description	Management
≤2	Mild	<ul> <li>✓ Occasional barky cough</li> <li>✓ no stridor at rest</li> <li>✓ mild or no retractions</li> </ul>	<ul> <li>✓ Home treatment –Symptomatic care including antipyretics and oral fluids</li> <li>✓ Outpatient treatment – Single dose of oral dexamethasone 0.15 to 0.6 mg/kg (maximum 16 mg) or oral prednisolone (1 mg/kg)</li> </ul>
3 to 7	Moderate	<ul> <li>✓ Frequent barky cough stridor at rest</li> <li>✓ mild to moderate retractions</li> </ul>	<ul> <li>Single dose of oral dexamethasone 0.6 mg/kg (max 16 mg)</li> <li>Nebulized Epinephrine 0.5ml/Kg (max dose infants 2.5ml, children 5.0ml)</li> <li>Hospitalization is generally not needed but may be warranted for persistent or worsening symptoms after treatment with glucocorticoid and epinephrine</li> </ul>
8 to 11	Severe	<ul> <li>✓ Frequent barky cough</li> <li>✓ stridor at rest</li> <li>✓ marked retractions significant distress</li> </ul>	<ul> <li>Single dose of oral/IM/IV dexamethasone 0.6 mg/kg (maximum 16 mg)</li> <li>Repeated doses of nebulized epinephrine may be needed</li> <li>O2 in non threatening manner</li> <li>Inpatient admission is generally required unless marked improvement occurs after treatment with glucocorticoid and nebulized epinephrine</li> </ul>
≥12	Impending respiratory failure	<ul> <li>✓ ↓consciousness</li> <li>✓ stridor at rest</li> <li>✓ severe retractions</li> <li>✓ poor air entry</li> <li>✓ cyanosis or pallor</li> </ul>	<ul> <li>Single dose of IM/IV dexamethasone 0.6 mg/kg (maximum 16 mg)</li> <li>Repeated doses of nebulized epinephrine may be needed</li> <li>O2 in non-threatening manner</li> <li>PICU admission is generally required</li> <li>Consultation with anesthesiologist or ENT surgeon may be warranted to arrange for intubation in a controlled setting</li> </ul>



### **Pediatric Pearls**

- •
- Always rule out a foreign body (FB) Since patients deteriorate rapidly, educate parents about worsening of symptoms. Steroids are useful.
- Nebulize Epinephrine at the right doses



## CHAPTER-8 CYANOTIC SPELL

Hyper cyanotic (or "Tet") spells present as periods of profound cyanosis that occur because of episodes of almost total RVOT obstruction.

It is commonly seen with Tetralogy of Fallot; may also be seen in other Cyanotic Congenital heart diseases like tricuspid atresia with restrictive VSD, VSD with severe PS.

#### **Precipitating factors**<sup>23</sup>:

- □ Sympathetic stimulation, including pain and anxiety (e.g., during venipuncture)
- □ Exercise
- $\hfill\square$  Breath holding or Valsalva maneuver
- $\Box$  Crying, feeding, and defecation
- □ Vasodilatation and decrease in SVR (e.g., hot baths)
- 🗆 Hypoxia
- □ Hypercarbia
- □ Acidosis
- □ Induction of anesthesia
- □ Sympathomimetic drugs

#### **Common age of Presentation**<sup>25</sup>:

Less than 2 years, peaking around 4-6 months

#### Clinical presentation<sup>23</sup>:

□ Classically, the child becomes restless, agitated, and breathless.

□ Older children may squat into a knee-to-chest position as a learnt mechanism to increase SVR and consequently reduce right-to-left shunt.

- $\Box$  The child will be cyanosed and tachycardic.
- $\Box$  A reduced murmur may be heard because of reduced blood flow through the RVOT.
- $\Box$  In severe attacks, the conscious level may fall or the patient may have a seizure.



### Treatment<sup>24,25</sup>:

Management is aimed at improving oxygenation, decreasing obstruction to right ventricular outflow, increasing pulmonary blood flow and systemic vascular resistance.

INTERVENTION	Mechanism of action
knee-chest position	Increases systemic vascular resistance (SVR), which
	promotes movement of blood from the RV into the
	pulmonary circulation
Oxygen – Nonthreatening manner	Pulmonary vasodilator and a systemic vasoconstrictor.
Intravenous (IV) fluid bolus (normal saline	Fluids improve RV filling and pulmonary flow.
10 to 20 mL/kg)	
IV morphine (0.1 mg/kg per dose) or	Reduces hyperpnea
intranasal fentanyl or midazolam	
IV beta blocker (e.g., propranolol 0.1	relaxation of the RVOT with improved pulmonary blood
mg/kg per dose or esmolol 0.1 mg/kg per	flow.
dose). If single doses are ineffective, a	
continuous IV infusion of esmolol (50 to 75	
mcg/kg/min) can be provided.	
Sodium Bicarbonate 1-2meq/kg IV	Corrects established acidosis
IV phenylephrine (bolus dose of 5 to 20	increases systemic afterload which promotes RV flow
mcg/kg per dose followed by continuous	into the pulmonary circulation rather than the aorta.
infusion)	
Ketamine 0.25-1mg/kg IV	Increases systemic vascular resistance and cause sedation

If the spell does not abort, the child needs to be shifted to the PICU for esmolol/propranolol and phenylephrine infusion and plan for emergency shunting procedure.



## CHAPTER-9 DIABETIC KETOACIDOSIS

Diagnose DKA in children and young people who have.

□ Acidosis (indicated by blood pH below 7.3 or plasma bicarbonate below 15 mmol/litre) and

□ Ketonemia (indicated by blood beta-hydroxybutyrate above 3 mmol/litre)

Blood glucose levels are generally high (above 11 mmol/l) but children and young people with known diabetes may develop DKA with normal blood glucose levels.

#### Clinical Presentation<sup>26</sup>:

Clinical History:

- 🗆 Polyuria
- □ Polydipsia
- □ Weight loss
- □ Abdominal pain
- □ Weakness
- □ Vomiting

### **Clinical Signs:**

- □ Clinical dehydration
- □ Deep sighing respiration (Kussmaul)
- $\Box$  Smell of ketones
- □ Lethargy, drowsiness

#### Management:

General resuscitation: Airway, breathing and circulation

Initial fluid bolus

All children and young people with mild, moderate or severe DKA who are not shocked and are felt to require IV fluids should receive a 10 ml/kg 0.9% sodium chloride bolus over 60 minutes.
 Patients with shock require appropriate restoration of their circulation and circulatory volume.
 Shocked patients should receive a 20 ml/kg bolus of 0.9% saline over 15 minutes.



□ Following the initial 20 ml/kg bolus shocked patients should be reassessed and further boluses of 10 ml/kg may be given if required to restore adequate circulation up to a total of 40 ml/kg at which stage inotropes should be considered.

□ Once circulating blood volume has been restored and the child adequately resuscitated, calculate fluid requirements as follows:

 $\Box$  Requirement = Deficit + Maintenance

Assume a 5% fluid deficit in children and young people in mild DKA (indicated by a blood pH 7.2-7.29 &/or bicarbonate <15)

Assume a 7% fluid deficit in children and young people in moderate DKA (indicated by a blood pH of 7.1- 7.19 &/or bicarbonate <10)

Assume a 10% fluid deficit in children and young people in severe DKA (indicated by a blood pH <7.1 &/or bicarbonate <5)

 $\Box$  Maintenance fluid volumes should be calculated using the Holliday – Segar formula

 $\Box$  The deficit should be replaced over 48 hours alongside appropriate maintenance fluids

 $\Box$  Hourly rate = ({Deficit – initial bolus} / 48hr) + Maintenance per hour

□ Use 0.9% sodium chloride with 20 mmol potassium chloride in 500 ml (40 mmol per litre) until blood glucose levels are less than 14 mmol/l.

 $\Box$  Once blood glucose < 14mmol add 5% glucose to 0.9% sodium chloride with 20 mmol KCl per

500 ml. Reduce insulin infusion to 0.05 units/kg/hr

#### Insulin:

□ Once rehydration fluids and potassium are running, blood glucose levels will start to fall. There is some evidence that cerebral oedema is more likely if insulin is started early. Do not give bolus doses of intravenous insulin.

□ Therefore, start an intravenous insulin infusion 1-2 hours after beginning intravenous fluid therapy

 $\Box$  Use a soluble insulin infusion at a dosage between 0.05 and 0.1 units/kg/hour.

#### **Bicarbonate:**

□ Do not give intravenous sodium bicarbonate to children and young people with DKA. Only consider bicarbonate if there is life threatening hyperkalemia or in severe acidosis with impaired myocardial contractility.



#### **Cerebral Oedema:**

Immediately assess a child or young person with DKA for suspected cerebral oedema if they have any of these early manifestations:

- □ Headache
- □ Agitation or irritability
- □ Unexpected fall in heart rate
- □ Increased blood pressure

If a child or young person develops any of these signs -

- □ Deterioration in level of consciousness
- $\Box$  Abnormalities of breathing pattern, for example respiratory pauses &/or drop in SaO2.
- $\Box$  Oculomotor palsies
- $\Box$  Abnormal posturing
- □ Pupillary inequality or dilatation.

Treat them Immediately for cerebral oedema using the most readily available of

- □ Hypertonic saline (2.7% or 3% 2.5-5 ml/kg over 10-15 minutes) or
- □ Mannitol (20% 0.5-1 g/kg over 10-15 minutes)
- □ Neuro-protection bundle
- $\Box$  In addition, fluids should be restricted to 1/2 maintenance rates
- $\hfill\square$  Inform pediatric intensivist immediately.



## CHAPTER-10 DIARRHEA WITH DEHYDRATION

□ Acute diarrhea is the second leading cause of under-five mortality in India.

 $\Box$  It is defined as the passage of frequent watery stools (>3/24 h). Recent change in consistency of stools is more important than frequency.

□ Acute diarrhea is caused by variety of viral, bacterial and parasitic agents. The common ones are: Rotavirus, E. coli, Shigella, Cholera, and Salmonella. Campylobacter jejuni, Giardia and E. histolytica are also not uncommon

#### Clinical Evaluation<sup>27</sup>:

The objectives of initial clinical evaluation of the patient in emergency department are:

- □ Assessment of the severity of the illness, grade of dehydration and rehydration needs.
- $\Box$  Identification of likely causes on the basis of the history and clinical findings.

A rapid assessment of airway, breathing and circulation should be done in all children at presentation. Tachycardia, prolonged capillary refill time, decreased urine output, altered mental status and hypotension indicates presence of shock and calls for oxygen, and fluid resuscitation with 20 ml/kg normal saline bolus.

Classification	No Dehydration	Some dehydration	Severe dehydration
Clinical features	No signs of	Two or more of the	Two or more of the
	dehydration	following Restless	following
		irritable	Lethargy
		Sunken eyes Very	Coma
		thirsty	Sunken eyes
		Skin pinch goes back	Not able to drink water
		slowly	Skin pinch goes back slowly
Investigations			Blood urea nitrogen
			Serum creatinine Serum
			electrolytes complete blood
			count
			Urine and stool tests as
			appropriate
Rehydration	none	ORS 50 – 100ml/kg	RL/NS in 20ml/kg body
therapy		ORS over 3 to 4 hours	weight till perfusion and

#### Management<sup>27,28</sup>:



			1	
Replacement of losses	<10kg- 60 to 120ml of ORS/stool >10kg- 120 to 240ml of ORS/stool	<10kg- 50 to 100ml of ORS/stool >10kg- 100 to 200ml of ORS/stool	mental status improves then administer 100ml/kg of ORS over 4 hours or 5% dextrose with ½ saline IV at twice the maintenance fluid rate <10kg- 50 to 100ml of ORS/stool >10kg- 100 to 200ml of ORS/stool If unable to drink, administer	
			same volume via NG or IV 5% dextrose with ½ saline in same dose	
Nutrition	Continue breast feeding Age-appropriate normal diet Assure adequate calorie intake	Continue breast feeding Age-appropriate normal diet Assure adequate calorie intake	Continue breast feeding Age-appropriate normal diet Assure adequate calorie intake	
Zinc therapy	Zinc supplements are given for 10–14 d during and after diarrhea in the doses of 10 mg/kg for infants < 6 month of age and 20 mg/d for the children >6 month of age			
Antimicrobial therapy	<ul> <li>✓ Diarrhea with clinical signs of sepsis</li> <li>✓ Diarrhea in a child with severe malnutrition</li> <li>✓ Neonates and very young infants (&lt; 3month) with fever (&gt; 38.5°C)</li> <li>✓ Dysentery (bloody stools) and diarrhea during outbreak of shigellosis</li> </ul>			



### CHAPTER-11 DISC BATTERY INGESTION

□ An increasing number of button battery (BB) ingestions has been described worldwide, mainly because of the wide abundance of batteries in consumer electronics.

□ Recognizing BB ingestion is very important because of the extremely narrow 2-hour time window to remove BB impacted in the esophagus.<sup>29</sup>

#### **Clinical features:**

□ Presenting symptoms differ according to the impaction site. Most witnessed ingestions present with acute gastrointestinal or respiratory symptoms, such as vomiting, drooling, dysphagia, odynophagia, irritability, coughing, stridor, and shortness of breath.

□ Illustratively, most complications occur after unwitnessed ingestions leading to delayed diagnosis, as symptoms are variable and nonspecific.

 $\Box$  Esophageal battery impaction has the highest risk of complications, especially in children <6 years of age and in batteries >20 mm in diameter.

#### Investigations:

□ Two-view (anterior-posterior and lateral) X-ray is paramount to diagnose BB ingestion and confirm its location.

□ Contrast studies with CT scanning (or MRI scanning after battery removal only) are necessary to identify complications, such a mediastinitis, fistulas, and spondylodiscitis.

 $\Box$  In delayed diagnosis of an esophageal impaction (first confirmation of the BB on X-ray >12 hours after ingestion or time point of removal >12 hours after ingestion) regardless of symptoms (serial) CT/MRI scans of the chest and neck should also be considered as the BB may have been lodged in the esophagus previously.

#### Management:

Esophageal and Airway Impaction:

□ When the battery is located in the esophagus, immediate endoscopic removal is necessary, if possible, within 2 hours of ingestion.



□ If the ingested battery is located in the airway or in the gastrointestinal tract above the clavicles, an ENT doctor should be consulted to remove objects from the upper airways or upper part of the esophagus by rigid endoscopy.

Location Beyond the Esophagus

□ Once the BB passed the esophagus almost three-quarters of ingested batteries pass spontaneously within 4 days. According to the NASPGHAN guideline, removal is, therefore, advised if a BB is still in the stomach after 2 to 4 days.

□ ESPGHAN recommends that once the BB has passed the esophagus, asymptomatic cases should be followed-up after 7 to 14 days with an X-ray to confirm passage unless the battery has been noticed in the stools by the parents. Only if the battery still has not passed the stomach by 7 to 14 days, endoscopic removal is necessary as by then the chance that it will pass spontaneously is expected to be minimal.

□ Removal of gastric BB is necessary in symptomatic cases, in case of co-ingestion with a magnet or in delayed diagnosis.

#### pH Neutralization Strategies to Mitigate Injury Progression After Ingestion:

□ Mitigation strategies with honey and sucralfate can be considered in specific cases while waiting for endoscopy but should not delay it.

 $\Box$  early and frequent ingestion of honey, and if available, sucralfate in the clinical setting may have the potential to reduce injury severity and improve patient outcomes.

 $\Box$  Another mitigation strategy is neutralization of accumulated tissue hydroxide through acetic acid irrigation immediately. following battery removal and may be considered an option. This can be done with 50 to 150 mL 0.25% sterile acetic acid and should only be considered if signs of perforation are absent.



### CHAPTER-12 GENERAL APPROACH TO A CHILD WITH POISONING

Poisoning is a commonly encountered pediatric emergency.

Recognition of the Child with Poisoning

- Acute onset of symptoms in a previously well child.
- Circumstantial evidence- empty bottles, tablets, spillage of household chemical near child.
- History may be available in a few cases

#### Management

- 1. Cardiopulmonary assessment and support of Airway, Breathing and Circulation.
- 2. Prevention or reduction of absorption
- 3. Enhancement of excretion
- 4. Supportive treatment
- 5. Administration of antidote

1. Cardiopulmonary assessment and support of Airway, Breathing and Circulation. Initial management consists of stabilization of Airway, Breathing and Circulation.

Indications for RSI

- Depressed sensorium GCS < 8 or fall in GCS by 2 from the time of initial assessment.
- Absent / poor cough & gag reflex.
- Hypoventilation.
- Fluid/catecholamine unresponsive shock.
- Severe metabolic acidosis.

Sensorium needs to be assessed by GCS or AVPU at hourly intervals until the situation is under control.

Papillary size and reaction need to be checked

Check blood sugar (bedside)



If hypoglycemic – treat with 10% dextrose 5ml/kg bolus.

If bedside sugar is not available – trial of 10% dextrose 5ml/kg can be given in all patients with altered sensorium.

In all patients with depressed sensorium +/- depressed respiration, a trial of IV Naloxone 0.1mg/kg (max 2mg can be given).

Expected response - increase in rate & depth of respiration, improvement in sensorium.

- 2. Prevention / Reduction of Absorption
- a) Skin Decontamination
- Particularly in organo phosphorous poisoning.
- Remove clothes.
- Clean skin / eyes with copious amounts of water.
- Medical personnel to take appropriate precaution by wearing gloves, protective clothing while handing.

#### b). Gastric Decontamination

i. Gastric Lavage

Useful only if patient arrives within 1 hour of ingestion of toxin.

#### Contra Indicated

- If Protective airway reflexes are lost
- Hydrocarbon/Corrosive poisoning
- Injury to GI Tract

#### Method

• Large bore single lumen (24-32f) NG/OG tube.

• After confirming position, normal saline (NS) 10-15ml/kg to be instilled & withdrawn repeatedly until clear fluid is aspirated.

ii. Activated charcoal (AC)Binds to toxin & reduces absorption.Indications



In patients presenting up to 4 hours after toxin ingestion.

Not useful (PHAILS – Mnemonic)

- P Pesticide (Rodenticide)
- H Hydrocarbon
- A -Acid, Alkaline, Alcohol'
- I -Iron
- L -Lithium
- S -Solvents

Dose: 1g/kg Administered as slurry via NG tube.

Ensure the airway is adequately protected.

In children with normal sensorium, can be taken orally as a slurry mixed with juice/ cool drink to improve palatability.

Contra Indication Absent airway reflexes. Not useful in poisons not absorbed by activated charcoal (PHAILS).

iii. Multiple doses Activated Charcoal

Indications

- Salicylates.
- Tricyclic anti-depressants.
- Sustained release / Enteric coated tablets.

3. Enhancement of Excretion:Whole Bowel Irrigation (WBI)

<sup>•</sup> Substances with increased enterohepatic circulation – Phenobarbitone, Carbamazepine, Theophylline.



Indication – Iron poisoning, Sustained release preparations.

Dose - 30ml/kg/hr 9500ml/hr) of polyethylene glycol given through nasogastic tube

End Point – Clear effluent after several hours.

Contra – Indications – Absent airway reflexes, GI bleeds, bowel obstruction or perforation

### 4. Supportive Management

- Shock / hypotension'
- Electrolyte imbalance
- Metabolic disturbance
- Bleeding
- Liver failure
- Psychiatry referral where relevant

5. Antidotes commonly available

Drug	Antidote and dosage		
Acetaminophen	N - acetylcysteine 150mg/kg over 15 min, 50mg/kg, over 4hrs,		
	100mg/kg over 16 hrs/Oral-140mg/kg, then 70mg/kg every 4hrs for		
	doses.		
Organophosphates	Atropine 0.05mg/kg doubled every 3-5min until symptoms resolve		
	Pralidoxime if patient has muscle weakness, respiratory depression within 36		
	hrs of ingestion 25-50mg/kg over 30-60 min then 10-20mg/kg/hr.		
Iron	Deferoxamine 15mg/kg/hr up to 6-8g/day		
Opiates	Naloxone 0.05-0.1mg/kg titrated to symptom reversal.		
Methemoglobinemia	Methylene Blue 1-2 mg/kg over 5 min		
(Commonly seen			
with dapsone &			
INH)			
Valproic Acid	L- carnitine 100mg/kg in for divided doses.		
induced.			
Hyperammonemia			
or elevated			
AST/ALT			

#### Medico legal notification needs to be done in all cases of poisoning - accidental or intentional.

Pediatric Pearls			
Antidotes and Drugs used in poisoning.			
■ N – acetylcysteine			
<ul> <li>Atropine</li> </ul>			
<ul> <li>Desferrioxamine</li> </ul>			



- Naloxone
- Methylene Blue
- L Carnitine
- Activated Charcoal
- Polythylene glycol

# Common house hold items of low toxicity

Children often ingest many household items kept within their reach due to their curious nature. Most of these unintentional ingestions are usually in small quantities only. Some of these are harmless and require only reassurance.

A list of substances that are harmless and require no treatment apart from reassurance is mentioned below.

 $\square$  Bar soap, Shampoo, hand lotion, creams, detergents, toothpaste, shaving cream and lotion

- $\hfill\square$  Clay, dehumidifying packets, crayon, candle, chalk
- $\Box$  Thermometer, pencil, Ink

Removal necessary large amount ingested for -

Colognes, after shave lotion, hair tonic, deodorants, hair dyes, >20match sticks Devices used for CPAP delivery (Patient interface)



# CHAPTER-14 HYPERTENSIVE CRISIS IN CHILDREN

The definition of HTN in the pediatric population has evolved with the development of evidencebased normative data based on age, sex, and height percentile.

Prehypertension <sup>1,2</sup>	Pediatric HTN <sup>1,2</sup>	Stage 1 HTN <sup>1,2</sup>	Stage 2 HTN <sup>1,2</sup>
SBP and/or DBP	SBP and/or DBP $\geq$ 95th	SBP and/or DBP	SBP and/or DBP
measurements that range	percentile for sex, age,	measurements that range	measurements that are
from the 90th percentile	and height percentile on	from the 95 <sup>th</sup> percentile	>5 mmHg above the
to less than the 95th	$\geq$ 3 separate occasions.	to 5 mmHg above the	99th percentile
percentile.		99th percentile	

Hypertensive crisis <sup>1,2</sup> : used to describe an acute elevation in BP that can cause rapid end-organ damage		
Hypertensive urgency	Hypertensive emergency	
✓ Elevated BP without the presence of	✓ Elevated BP with acute target-organ injury.	
acute target-organ damage.	<ul> <li>Organ injury occurs in the central nervous</li> </ul>	
<ul> <li>May manifest symptoms such as</li> </ul>	system, kidneys, or cardiovascular system	
headache and nausea		

# LAB investigations<sup>30</sup>:

Initial investigations in the ED depend on findings from the history and physical exam

□ Urinalysis: Presence of hematuria and proteinuria

□ Serum chemistries: blood urea nitrogen, creatinine for baseline renal function, as well as for

evidence of hypokalemic alkalosis found in HTN associated with renal vein stenosis

 $\Box$  Compete blood count

□ Electrocardiogram and chest X-ray should be considered to evaluate for signs of congestive heart failure or myocardial hypertrophy.

□ Computed tomography of the head may be warranted in the presence of abnormal neurological findings.

# Management 30,31:

□ The majority of mild-to-moderate pediatric HTN seen in the ED does not require immediate intervention. These cases mandate close outpatient follow-up, evaluation, and management.



□ Hypertensive crises, however, necessitate immediate intervention to safely and effectively lower the BP. Current recommendations advise no more than a 25% reduction of SBP in the first 8 hours, followed by a gradual return to normal BP over 26 to 48 hours.

□ Hypertensive emergencies are most commonly treated with intravenous (IV) medications. This allows for easier titration and control of the rate of decrease in BP.

□ Rule out elevated intracranial pressure before lowering BP.

Most Useful		1		
Drug	Class	Dose	Route	Comments
Esmolol	β-blocker	100–500 mcg/kg/min	IV infusion	Very short-acting—constant infusion preferred. May cause profound bradycardia. Produced modest reductions in BP in a pediatric clinical trial.
Hydralazine	Vasodilator	0.2–0.6 mg/kg/dose	iv, im	Should be given every 4 hours when given iv bolus. Recommended dose is lower than FDA label.
Labetalol	α- and β- blocker	bolus:0.2–1 mg/kg/dose up to 40 mg/dose infusion: 0.25– 3.0 mg/kg/hr	iv bolus or infusion	Asthma and overt heart failure are relative contra-indications.
Nicardipine	Calcium channel blocker	1–3 mcg/kg/min	iv infusion	May cause reflex tachycardia.
Sodium nitroprusside	Vasodilator	0.53–10 mcg/kg/min	iv infusion	Monitor cyanide levels with prolonged (>72 hr.) use or in renal failure; or co-administer with sodium thiosulfate.
Occasionally use	eful			·
Clonidine	Central α-agonist	0.05–0.1 mg/dose may be repeated up to 0.8 mg total dose	ро	Side effects include dry mouth and sedation.
Enalaprilat	ACE inhibitor	0.05–0.1 mg/kg/dose up to 1.25 mg/dose	iv bolus	May cause prolonged hypotension and acute renal failure, especially in neonates.
Fenoldopam	Dopamine receptor agonist	0.2–0.8 mcg/kg/min	iv infusion	Produced modest reductions in BP in a pediatric clinical trial in patients up to 12 years.
Minoxidil	Vasodilator	0.1–0.2 mg/kg/dose	ро	Most potent oral vasodilator; long-acting.
Isradipine	Calcium channel blocker	0.05–0.1 mg/kg/dose	ро	Stable suspension can be compounded.



# **Pediatric Pearls**

- Gradually reduce blood pressure Avoid sublingual Nifedipine. Aggressively evaluate for etiology and end organ damage Check the fundus



# CHAPTER-15 IRON POISONING

**Source:** Iron capsules, liquid preparation or chewable iron tablets Liquid formulations and chewable iron are not radiopaque. Toxic dose: more than 60mg/kg of elemental iron.

#### **Mechanism of Toxicity**

Due to direct caustic effects on the GI mucosa & presence of free iron in the circulation.

#### **Clinical Presentation**

1. Stage of GI Symptoms (Less Than 6hrs)

□ GI symptoms like vomiting, abdominal pain – early onset indicates severe toxicity.

□ Doses of 30mg/kg of elemental iron could cause GI symptoms.

 $\Box$  If there are no GI symptoms up to 6hrs post ingestion, it is unlikely that there is significant toxicity.

# 2. Stage of Relative Stability (6-24hrs)

GI symptoms subside and child appears stable.

Subtle signs of mild GI bleeding, hyperventilation, prolonged CFT may go unnoticed.

# 3. Stage of Shock (24-48HRS)

This is the stage of significant shock, metabolic acidosis & even GI bleeding. Shock could be a combination of hypovolemic, distributive and myocardial components.

# 4. Hepatotoxic Stage (may start after 2-3days)

In this stage, features of liver failure are evident through elevated liver enzymes and prolonged prothrombin time.

# 5. Stage of Gastric Scarring (2-6weeks) Post Ingestion

Gastrointestinal strictures are formed.



# Management

Investigations

**X** – **Ray Abdomen:** To look for concretion of iron capsules. (Presence of radiographic evidence and severe metabolic acidosis indicates significant toxicity).

 $\Box$  Serum Iron Levels : Through not readily available, can be used to predict outcome

- <350mcg/dl -mild
- 350-500mcg/dl -moderate
- >500mcg/dl severe toxicity
- □ Total Blood Count may reveal leukocytosis
- $\hfill\square$  Blood sugar usually more than 150mg/dl
- □ S-Electrolytes particularly serum HCO3
- □ BUN, Creatinine, LFT.

# Treatment

Assess & stabilize Airway, Breathing and Circulation.

# Decontamination

□ NG or Orogastric Lavage: Limited by the tube size through which effective evacuation of iron concretions are not possible.



# CHAPTER-16 KEROSENE POISONING

□ Kerosene is an aliphatic hydrocarbon commonly used in households and industries, especially in developing countries.

 $\Box$  It is used in households for cooking, lighting, heating, and in paints and pesticides.

□ Exposure occurs accidently in children when they consume the kerosene stored in juice bottles, beverages bottles, and colorful packing within their reach.

# Mechanism of Toxicity<sup>34</sup>

□ Due to its low viscosity, low surface tension, and high volatility, there are high chances of aspiration, which usually occurs at the time of ingestion (coughing and gagging) or vomiting (spontaneous or induced) after ingestion.

 $\Box$  Aspiration of even small amounts of kerosene (<1 mL) can lead to serious, potentially life-threatening toxicity.

□ Kerosene once aspirated spread rapidly across the surfaces of airway and alveoli leading to inactivation of type II pneumocytes, and resulting surfactant deficiency, intra-alveolar hemorrhage, inflammation, and necrosis.

Respiratory	Tachypnea, dyspnea, cyanosis, grunting, bronchospasm, intercostal		
system	retractions, use of accessory muscles		
	On auscultation, decreased breath sounds, diminished resonance, bronchial		
	breath sounds, crepitations		
Central nervous	Drowsiness, which is often mild and transient.		
system	Other signs of CNS impairment include restlessness,		
	stupor, and convulsions, dizziness, euphoria, headache		
Gastrointestinal	Vomiting, abdominal pain, constipation,		
system	nausea, diarrhea and Malena		
Fever	Fever, often seen within 30 minutes, is		
	generally triggered by inflammatory response due		
	chemical irritation.		
	However, if the fever persists beyond 48 hours, bacterial infection should be		
	considered		

# Clinical Features<sup>33</sup>



# Investigations<sup>34</sup>:

#### **Chest X ray:**

□ Indicated in all children with a history of kerosene ingestion and respiratory symptoms.

□ Chest radiographs may be normal initially but may show abnormalities within 6 hours of aspiration in the majority of symptomatic cases.

□ Typical radiographic findings are increased broncho vascular markings and infiltrate involving bibasilar and perihilar regions. Lobar consolidation, pneumothorax, pneumomediastinum, and pleural effusion are uncommon.

Arterial blood gas to know about oxygenation and ventilation status in children with respiratory distress as well as the need for escalation of respiratory support and response to it.

# Management<sup>34</sup>:

 $\hfill\square$  The mainstay of treatment for kerosene poisoning is supportive care.

 $\Box$  Remove the patient from exposure and remove soiled clothing

□ In the case of accidental ingestion, the emesis and gastric lavage are contraindicated as there is a higher risk of aspiration than systemic absorption.

□ There is no clear role of corticosteroids or prophylactic antibiotics. Antibiotics are reserved for children with definite evidence of infection.

□ If aspiration pneumonitis develops, the respiratory treatment is supportive. The airway patency should be evaluated and established. Any child with respiratory symptoms (grunting, tachypnea, or cyanosis) should be started on humidified oxygen and requires an arterial blood gas analysis. Oxygen support, respiratory monitoring, intake and output monitoring, and supportive care are important management strategies. It is important to realize that children with respiratory compromise at presentation to the emergency department can suffer rapid deterioration.

□ For children who have severe distress with hypoxemia unresponsive to supplemental oxygen and/or severe central nervous system involvement require early intubation and mechanical ventilation.



# CHAPTER-17 NAPHTHALENE POISONING

#### Source<sup>35,36</sup>: Mothballs, Toilet bowl deodorizers.

 $\hfill\square$  The naphthalene content of one mothball varies from 0.5 to 5 g.

□ The fatal dose of naphthalene in children is unknown, but even one mothball can result in toxicity, and there are reports of deaths following the ingestion of naphthalene balls.

□ The absorption of naphthalene from GIT is erratic in the pediatric population. Other routes of exposure are inhalation and skin contact.

# Clinical Features<sup>35</sup>:

- $\Box$  Headache
- □ Vomiting
- 🗆 Diarrhea
- $\Box$  Abdominal pain
- □ Fever
- $\Box$  Altered mental status.

□ Significant clinical manifestations in naphthalene poisoning occur due to hemolysis leading to anemia, jaundice, hemoglobinuria, methemoglobinemia, and acute kidney injury.

 $\Box$  Skin exposure – dermatitis

# Investigations<sup>35</sup>:

- □ Complete blood count, peripheral blood film for evidence of hemolysis
- $\Box$  Urine and plasma hemoglobin
- □ Lactate dehydrogenase (LDH)
- $\Box$  Renal and liver function tests
- □ Acid–base status
- $\Box$  Urine routine examination
- □ Methemoglobin levels
- $\Box$  G6PD levels need to be monitored in children with naphthalene poisoning.



#### Management<sup>37</sup>:

#### Specific Treatment –

 $\Box$  Specific treatment includes the use of methylene blue and exchange transfusion.

Exchange transfusion is the treatment of choice in patients with G6PD deficiency as methylene blue itself may induce hemolysis and cause paradoxical methaemoglobinaemia in these patients.
 NAC may be used in the treatment of methaemoglobinaemia as a reducing agent especially in patients with G6PD deficiency.

#### Supportive Treatment –

□ Supportive treatment to maintain the airway, breathing and circulation (which may include endotracheal intubation, mechanical ventilation and use of inotropes).



# CHAPTER-18 ORGANOPHOSPHATES POISONING

There are 2 groups of organophosphorus compounds: organophosphates and carbamates.

#### Source:

Organophosphates: - malathion, parathion, HETP

Carbamate: Baygon, Carbofiran

#### **Mechanism of Poisoning**

Inhibition of acetylcholinesterase, thereby causing increased cholinergic activity.

#### Clinical syndrome<sup>35</sup>

1. Acute Toxicity:

Muscarinic effects	(SLUDGE), Salivation, Lacrimation, Urination, Defecation,	
	Gastrointestinal cramps, emesis.	
Nicotinic effects	Fasciculations, weakness, flaccidity.	
CNS effects	Seizures, agitation, coma, delirium.	
CVS	Bradycardia, heart block, cardiac arrest.	
RS	Bronchorrhea, bronchospasm.	
Eyes	Miosis, blurred vision.	

- 2. Intermediate syndrome:
- □ Occurs 24-96 hours after exposure.
- □ Bulbar, respiratory, and proximal muscle weakness are prominent features.
- $\Box$  Generally, resolves in 1-3 weeks.
  - 3. Organophosphorus Agent-Induced Delayed Peripheral Neuropathy (OPIDN):
- $\Box$  Usually occurs several weeks after exposure.
- $\Box$  Primarily motor involvement.
- $\Box$  May resolve spontaneously but can result in permanent neurologic dysfunction.

#### Management <sup>36,37</sup>:

Diagnostic evaluation of acute toxicity:



1. Atropine challenge if diagnosis is in doubt (1 mg IV in adults, 0.01 to 0.02 mg/kg in children)

□ Absence of anticholinergic signs (tachycardia, mydriasis, decreased bowel sounds, dry skin) strongly suggests poisoning with organophosphate or carbamate

2. Draw blood sample for measurement of RBC acetylcholinesterase activity to confirm diagnosis

#### General

 $\Box$  Check airway, breathing, and circulation.

□ Place patient in the left lateral position, preferably with head lower than the feet, to reduce risk of aspiration of stomach contents.

□ Provide high flow oxygen, if available. Intubate the patient if their airway or breathing is compromised

□ Effective skin & mucosal decontamination with copious amounts of water to prevent dermal absorption. May need to be repeated periodically, if dermal inoculation is the mode of poisoning.

#### **Specific Management**

1. Atropine:

□ Dose 0.05mg/kg I.V. bolus to be given every 10-15 minutes, dose may be doubled as required) Reverses muscarinic effects only end point for administration: Drying up to secretions, Tachycardia is not a contraindication for atropine.

 $\Box$  Repeat atropine dose 0.05mg/kg after 5 to 10 min if no improvement after first dose. Repeat boluses until heart rate is appropriate for age and systolic BP >5th centile and chest are clear

□ Once patient is stable, start infusion of atropine at approximately 20% of the cumulative bolus doses administered.

- 2. Pralidoxime:
- □ Cholinesterase reactivator
- □ Mechanism: regeneration of acetylcholinesterase

 $\Box$  Dose: 25-50mg/kg I.V over 20-30 min followed by infusion at 10 – 20mg/kg/hour in saline.

Continuing PAM infusion till atropine is no longer required for 12-24 hours and patient is extubated.



# CHAPTER-19 OPIATE TOXICITY

Source: Cough syrups containing codeine, Lomotil & opiate containing analgesics

# Clinical features<sup>39</sup>:

The classic findings of opioid toxicity are:

□ Miosis

□ Central nervous system (CNS) depression

□ Respiratory depression

□ Other findings, including hyporeflexia, hypothermia, dermal "track marks", flushing, pruritus,

bradycardia, hypotension, or decreased bowel sounds.

System	Manifestations
Pulmonary	Respiratory depression, noncardiogenic pulmonary edema
Cardiovascular	Orthostatic hypotension, peripheral vasodilation, dysrhythmias
Neurologic	Analgesia, euphoria, dysphoria, miosis, mydriasis, seizures
Gastrointestinal	Nausea, vomiting, constipation
Dermatologic	Flushing, pruritus
Reproductive	Amenorrhea, anovulation

# Ancillary studies<sup>39</sup>:

Children and adolescents with altered mental status and suspected opioid intoxication warrant the following studies:

□ Blood glucose.

□ Pulse oximetry and, if respiratory status does not improve after naloxone administration, blood gas measurement.

 $\hfill\square$  Serum acetaminophen concentration if suicidal intent or if ingestion of combination agents

(e.g., acetaminophen with hydrocodone or oxycodone)

□ Serum ethanol level (adolescents with recreational or suicidal overdose)

□ Electrocardiogram, especially in patients with methadone overdose to evaluate for prolonged QTc.

□ Chest radiograph, in patients with persistent respiratory findings suggestive of pulmonary aspiration or noncardiogenic pulmonary edema.



□ Rapid urine pregnancy test in post menarcheal girls

□ Urinalysis, serum electrolytes, blood urea nitrogen, creatinine, and creatine kinase in patients

at risk for rhabdomyolysis (e.g, prolonged immobilization, muscular rigidity)

# Management<sup>38,39</sup>

□ Support Airway, Breathing and Circulation

 $\hfill\square$  Continuous monitoring of SpO2, ECG and q15-30 min BP checks

 $\hfill\square$  Gastric lavage only if the child presents within 1 hour of consumption

□ Activated charcoal should be given only if patient is seen within 4 hours of ingestion & af6er protecting the airway.

# Specific Antidote:

Give naloxone for deep coma and respiratory depression as follows:

□ Children <20 kg: 0.1 mg/kg IV or IO (maximum 2 mg per dose) except neonates

 $\hfill\square$  Children over 20 kg: 2 mg IV or IO

□ Adolescents suspected of opioid dependents and overdose: 0.04 to 0.4 mg per dose repeated every 3-5 minutes and titrated to patient response

 $\Box$  If no effect, repeat the naloxone dose every one to two minutes to a maximum total dose of 10 mg

 $\Box$  Patients with recurrent toxicity may receive additional bolus doses or a continuous naloxone infusion. Begin the infusion rate at 2/3 of the total dose of naloxone needed to restore breathing, delivered every hour.

If the patient develops respiratory depression despite the naloxone infusion (this may happen 20 to 30 minutes after starting infusion) administer a naloxone bolus (using half the original effective bolus dose) and repeat, if necessary, until adequate ventilation returns, then increase the infusion rate.

If the patient develops signs of opioid withdrawal, stop the infusion. If respiratory depression returns, start the infusion at half the original rate.



# CHAPTER-20 PARACETAMOL TOXICITY

#### Toxic dose<sup>40</sup>:

>150 mg/kg in 24 hours	Child	
>7.5 gm in 24 hours	Adult / adolescent	

#### Clinical features<sup>40, 41</sup>:

Mean onset of symptoms is -6 hrs. after ingestion.

Stage	Time frame	Symptoms
1	0.5 – 24 h	Unspecific symptoms like
		diarrhea, nausea, malaise
2	24–48 h	Abdominal pain,
		abnormal laboratory values
3	3-4 days	Peak of hepatic dysfunction,
		stage 1 symptoms may reappear
4	4–14 days	Recovery or complete liver failure

#### Investigations<sup>41</sup>:

- All patients need a baseline measurement
- □ Electrolytes
- $\Box$  Liver enzymes
- $\Box$  Renal functions,
- □ Markers of coagulopathy
- $\Box$  ABG analysis


• If the patient was asymptomatic at presentation, the routine baseline investigations should be repeated after 48 hours.

• In symptomatic patients, they are done as and when required depending on the clinical status.

• Blood paracetamol level estimated after 4 hours of ingestion of a large single dose of paracetamol should be plotted against.

Rumack–Matthew nomogram to estimate the risk of toxicity and need for NAC (in asymptomatic patients).





#### Management<sup>41, 42</sup>:

□ Assess and support airway, breathing, circulation – Sensorium is usually normal in paracetamol poisoning.

- □ Gastric lavage only if child presents within 1 hour of ingestion.
- $\Box$  Activated charcoal 1 g/kg up to 4 hrs. after ingestion.

#### **Specific Antidote**

N-acetyl cysteine Oral or IV

#### Indication

- Patients who have ingested >150 mg/kg paracetamol are symptomatic.
- If the blood paracetamol level at 4 hours indicates toxicity(140–150  $\mu$ g/mL).
- Patients with delayed presentation (>24 hours after ingestion) and laboratory evidence of hepatotoxicity and a history of excessive acetaminophen ingestion.

#### Time of administration:



Ideally within 8 hrs. after ingestion. However, it can still be effective days after the ingestion, when patients are already in hepatic failure and acetaminophen levels are no longer detectable.

# Oral administration:

140 mg/kg first dose followed by 70 mg/kg every 4th hourly for 17 doses.

# IV – 21 hr. regimen:

	<20kg	20-40kg
Loading	150 mg/kg in 3 mL/kg of diluent given IV	150 mg/kg in 100 mL of diluent given IV
dose	over 60 minutes	over 60 minutes
Second	50 mg/kg in 7 mL/kg of diluent given IV	50 mg/kg in 250 mL of diluent given IV
dose	over 4 hours	over 4 hours
Third dose	100 mg/kg in 14 mL/kg of diluent given IV	100 mg/kg in 500 mL of diluent
	over 16 hours	administered over 16 hours

Adverse reaction with IV – Flushing, itching, hives to be treated with antihistaminic.

When to stop:

• Asymptomatic (e.g., no right upper quadrant pain)

• Acetaminophen concentration is nondetectable

• The serum transaminase activity is decreasing significantly (has decreased to the normal range or to <50 percent of the peak value)

King's College Hospital criteria for liver transplantation in paracetamol induced acute liver failure<sup>43</sup>.

• Arterial pH <7.3 (irrespective of the grade of encephalopathy)

OR

• Grade III or IV encephalopathy AND

Prothrombin time >100 seconds (INR>6.5) AND

Serum creatinine >3.4mg/dL (301 µmol/L)



# CHAPTER-21 POLYTRAUMA

#### The golden hour of stabilization:

#### **Primary survey:**

Includes stabilization Airway, Breathing and Circulation and disability (neurologic) assessment.

#### Airway and Breathing:

Maintain 'C' spine immobilization. ↓ Open airway by jaw thrust manoeuvres ↓ Administer O2 by face mask (if hypoxic)

#### Intubate (by RSI) if:

 $\Box$  GCS  $\leq$  8 or GCS falls by more than two from time of initial assessment

🗆 Hypoxia

 $\Box$  Increased work of breathing

- $\Box$  Flail chest is present
- □ Protective airway reflexes are lost
- □ Decompensated shock persists despite conventional management.

Use an orogastric tube to deflate the stomach.

Drugs for intubation in the hemodynamically stable child:

Atropine (0.02 mg/Kg, max 1 mg)

Lidocaine (1 mg/Kg, if TBI is also present)

Fentanyl (1-2  $\mu g/Kg$ )

Midazolam (0.1 mg/Kg) or Propofol (1-2 mg/Kg)

Paralyse with vecuronium (0.3 mg/Kg).

Drugs for intubation in the haemodynamically unstable child :



Atropine (0.02 mg/Kg), Lidocaine 1 mg /Kg (if TBI is also present) Ketamine 1-2mg/kg (in the absence of TBI) or Fentanyl (1-2 μg/Kg) Paralyse with Vecuronium (0.3 mg/Kg)

# **Circulation:**

Obtain two large bore IV accesses

```
\downarrow
```

Obtain samples for CBC, grouping and cross matching, PT, PTT (if bleeding) electrolytes, SGOT, SGPT, BUN, Se Creatinine

 $\downarrow$ 

If B. P < 5th centile, administer NS 20ml/Kg over 5-10 min and repeat x3 times till B.P improves.

 $\downarrow$ 

Consider blood loss (abdomen, retroperitoneum, pelvis, thigh, chest) if

B.P does not improve and transfuse PRBC 20ml/Kg

 $\downarrow$ 

Simultaneously start dopamine +/- noradrenaline infusion.

 $\downarrow$ 

Catheterise bladder if there is no blood at urethral meatus

# **Disability:**

Neurologic assessment is made initially by the GCS score and periodically reassessed; if <8, the child needs intubation.

If TBI is suspected, non contrast CT scan needs to be done.

# Secondary Survey:

Perform a detailed head to toe examination to asses extent of injuries.

Maintain 'C' spine immobilization.

Palpate for swelling and depression.

Control bleed

# Look for bruising / swelling over:



- Chest (rib fracture/underlying lung contusion)
- Abdomen (liver/splenic laceration) Auscultate chest (air entry)
- Consider needle throracostomy if pneumothorax is suspected

Auscultate abdomen (bowel sounds)

Look for blood at urethral meatus – if present do not catheterize bladder.

#### Choice of imaging

Chest X RAY – AP View

X-ray Neck-Lateral view

CT brain if TBI is suspected.

X – ray limb if fracture is suspected

Focused abdominal sonography in trauma (FAST), if there is doubt about Abdominal trauma and patient is too sick to be shifted to CT room.

CT abdomen with contrast is the imaging of choice when abdominal trauma is strongly suspected. Shift the child for imaging only when Airway Breathing and Circulation have been stabilized. Involve Pediatric surgeon, Neurosurgeon and Orthopedic surgeon in patient care after the child has been stabilized.

 Pediatric Pearls

 Maintain 'c' spine immobilization at all times



# CHAPTER-22 PYRETHRIN & PYRETHROID POISONING

Pyrethrin and synthetic pyrethroids are active ingredients of common house hold insecticides and mosquito repellants.

Most cases of pyrethrin toxicity are allergic reactions.

Synthetic pyrethroids cause no allergic reaction, but can cause systemic toxicity following ingestion, dermal exposure and inhalation.

Commercially available pyrethroids and their	clinical features <sup>1</sup> :
✓ Bifenthrin	✓ Cyhalothrin
✓ Permethrin	✓ Cypermethrin
✓ Phenothrin	✓ Deltamethrin
$\checkmark$ PR allethrin	✓ Fenvalerate
✓ Resmethrin	✓ Fenpropathrin
✓ Tefluthrin	✓ Tralomethrin
Type I syndrome "T syndrome"	Type II syndrome "CS syndrome"
✓ Severe fine tremor	✓ Choreoathetosis
✓ Marked reflex hyperexcitability	✓ Salivation
sympathetic activation.	✓ Coarse tremor
✓ Paresthesia (dermal exposure)	✓ Increased extensor tone
	<ul> <li>Moderate reflex hyperexcitability sympathetic activation</li> </ul>

# Diagnosis<sup>44</sup>:

The diagnosis of pyrethroid poisoning is based mainly on the clinical presentation and compound identification on the container brought by the patient or relatives.

# Management<sup>44,45</sup>:

□ Management is largely supportive and symptomatic because there is no available antidote.

□ Optimization of the airway, breathing, and circulation is vital.

□ Immediate decontamination of skin with soap and water can be considered; however, there is no evidence that it reduces toxicity.

□ Gastric lavage is best avoided in the case of pyrethroid ingestion as the risk of aspiration pneumonia with the solvent is high. Evidence for the use of activated charcoal is limited; however, this can be considered if the patient is present within 1 hour of ingestion.



# Systemic toxicity

- $\square$  Essentially supportive management
- $\hfill\square$  Benzodiazepines for tremors/ seizure.
- □ Topical Vitamin E for paraesthesia
- $\Box$  Supportive treatment for allergic reaction.

Majority of patients recover within 1-6 days without any neurological sequelae.



# CHAPTER-23 RODENTICIDE POISONING

Historically, various ingredients like strychnine, heavy metals, yellow phosphorous, and zinc phosphide have been used as rat poison. The majority of rodenticides we encounter today. Contain warfarin type anticoagulants and long acting brodifacoum also called superwarfarins (100 times > potent and longer acting 16-69 days).

#### Mechanism of action

Blockage of production of Vitamin K depends on coagulation factors.

#### Signs and symptoms

Bleeding manifestations Cardiac arrythmias, refractory shock or cardiac arrest Onset of symptoms may be delayed (In case of thallium, arsenic, SMFA)

#### Investigations

Complete Blood count

PT, aPTT, INR – Repeat daily up to 75 hours, even if initial values are normal Blood grouping/cross matching.

#### Management

Support of Airway, Breathing and Circulation

Gastric decontamination with activated charcoal 1g/kg with adequate airway protection. (Preferably those who present to ER <1hour of ingestion)

Antidote – Vitamin K 0.3 mg/kg I.V over 5 minutes q8hrs (Max – 10mg) if coagulopathic (INR>2) Prolonged Treatment with high dose may be needed. If frank bleeding – fresh frozen plasma transfusion needed.



# CHAPTER-24 SALICYLATE POISONING

#### Source:

Tablets containing aspirin, oil of wintergreen

#### **Clinical presentation**

Nausea, vomiting, hyperpyrexia, hyperventilation, tinnitus, coma, convulsions.

#### Less common

- □ Respiratory depression
- □ Pulmonary edema
- $\Box$  Acute tubular necrosis
- □ Hepatotoxicity
- $\Box$  SIADH

# Investigations

Arterial blood gas – in all suspected cases – Mixed respiratory alkalosis & metabolic acidosis S. Electrolyte, BUN, S. Creatinine, S. Ketones Salicylate level – Not available in most laboratories

#### **Treatment:**

Support Airway, Breathing and Circulation. Gastric lavage – limited value Activated charcoal – after protecting the airway Multiple doses of activated charcoal may be required (every 4-6 hours up to 6 doses)

# Increase elimination.

a. Alkalinixation 80-150 meq/l of sodium bicarbonate with 5% Dextrose to run at one and a half maintainance to maintain urine pH > 7. Add KCI to IVF 20-40 meq/l (to be checked every 6 hrs).
b. Dialysis



# Indication for hemodialysis

- □ Renal failure
- □ Congestive cardiac failure
- □ Extremely elevated salicylate levels (> 100mg/dl)



# CHAPTER-25

# **SCORPION STING – MANAGEMENT**

46,47,48

Grade	Manifestation	Treatment
Grade I	✓ Isolated pain	✓ Ice packs
		✓ NSAIDS
		✓ Local anesthetic agents
Grade II	✓ Hypertension	✓ Encourage IV fluids/IV fluids if oral
	✓ Sweating	intake is poor
	✓ Vomiting	✓ Antivenom
	✓ Priapism	✓ Prazosin(30mcg/kg) stat; repeat as and
	✓ Fever	when necessary
	✓ shivering	✓ Oral paracetamol if necessary
Grade III	✓ Cardiogenic shock	✓ Oxygen therapy
	✓ Pulmonary edema	✓ CVP guided fluid therapy
	✓ Altered	✓ Positive pressure ventilation if needed
	consciousness	✓ Antivenom
		✓ Dobutamine
		✓ Nitroprusside or nitroglycerine, if
		normotensive
		✓ Prazosin(30mcg/kg) stat; repeat as and
		when necessary
Grade IV	✓ Tachycardia	✓ Oxygen therapy
	$\checkmark$ Hypotension with	✓ CVP guided fluid therapy
	or without	<ul> <li>Positive pressure ventilation if needed</li> </ul>
	pulmonary edema	✓ Antivenom
		✓ Dobutamine
		✓ Prazosin(30mcg/kg) stat; repeat as and
		when necessary

# **Investigations:**

Aimed at identifying complications

 $\Box$  Electrocardiogram

 $\Box$  Chest X ray

 $\Box$  Echocardiography

□ Biochemical abnormalities: these are elevated potassium, amylase, lactate dehydrogenase levels, raised liver enzymes, glucose and free fatty acids, reduced cholesterol and triglyceride levels.

Pediatric Pearls
Do not use sustained release, use only crossed tablets or Prazosin



# CHAPTER-26 SEPTIC SHOCK

#### Definitions

Sepsis: Systemic inflammatory response syndrome caused by an infection.

Severe sepsis: Sepsis with at least one organ system dysfunction.

**Septic shock**: Sepsis with cardiovascular dysfunction causing inadequate supply & deficit of oxygen and metabolic substrates to tissues.

#### Management principles:

□ Document baseline observations and continue ongoing monitoring to assess the response to treatment.

□ Provision of supplemental oxygen by providing appropriate airway and ventilatory support.

□ Stabilization of cardiovascular function with fluid resuscitation to optimize preload and appropriate inotropic and vasoactive therapy to optimize perfusion pressure.

□ Treatment of underlying cause (antimicrobial therapy to cover likely pathogens, drainage of pus wherever appropriate).

#### Steps in management of child with septic shock:

1. Recognize septic shock and classify the physiological state:

# **Clinical definition:**

Presence of sepsis with any of the two signs of poor systemic perfusion mentioned below

- a. Decreased pulse volume (week or absent dorsalis pedis pulse)
- b. Prolonged capillary refill time (> 3 sec)
- c. Central (rectal/oral) to peripheral (toe skin) temperature defference  $> 3^{\circ}$  C
- d. Oliguria (< 1ml/kg/hour)
- e. Unexplained metabolic acidosis or increased lactate (> 2mmol)

 $Hypotension-Systolic \ BP < 5 th \ percentile \ for \ age: < 70 mmHg \ in \ infants; \ 70+ (age \ in \ years \ x \ 2)$ 

after one year of age. Hypotension occurs late in children with septic shock

2. Therapeutic end points and monitoring parameters



#### Breathing

- $\Box$  Normal respiratory rate for age
- □ Normal work of breathing (In the absence of pneumonia, lung pathology)

 $\Box$  SpO2 > 92%

#### Circulation

- $\Box$  Normal heart rate for age
- $\hfill\square$  Normal pulses with no difference between central and peripheral pulse
- $\Box$  Warm and pick extremities
- $\Box$  Capillary refill time < 2 s
- $\hfill\square$  Normal range of systolic BP for age with normal pulse pressure

#### Renal

 $\Box$  Urine output - > 1ml/kg/hour in children upto 50kg or 30-50 ml/hr in children weighing greater than 50kgs

#### Neurological.

- □ Return baseline mental status (AVPU scale) in a child who is not intubated and sedated.
- $\Box$  Brisk response to light and equal pupils in a sedated or paralyzed child.
- 3. Emergency department management of septic shock (Flow Chart 1)

Emergency management - Golden hour of sepsis management

- a. Recognition of shock state and providing respiratory support (0.5 min)
- b. Establishment of intravenous/intraosseous access and fluid resuscitation to Optimize preload
- (5-40min)
- c. Vasoactive drug therapy and Optimization of perfusion pressure (20-60 min)
- d. Correction of metabolic impairments (20-60 min)

□ The first dose of broad-spectrum antibiotic has to be given during the golden hour of resuscitation. Commonly used antibiotics include third-generation cephalosporin such as Ceftriaxone and aminoglycoside such as Amikacin for community acquired infections and immunocompromised patients to be treated accordingly.



□ While vasoactive drugs are instituted for restoration of cardiac output and perfusion pressure, hypoglycemia and hypocalcemia, both of which might impair cardiac performances should be corrected.

 $\Box$  Stress dose Hydrocortisone 50 mg/m2/dose stat followed by 50 mg/m2/day in 4 divided doses should be given in catecholamine resistant shock.



# CHAPTER-27 SNAKE ENVENOMATION

#### **Prehospital care**

# RIGHT

R: Reassure

I : Immobilise the bitten extremity in a neutral position

G: Go to

H: the Hospital

T : Tell the doctor about – ptosis, gum bleeds, abdominal pain (Krait bites) Constriction bands, pressure immobilization are not recommended.

If tourniquet has been applied, do not release it immediately.

#### **Supportive care:**

Support of Airway, Breathing and Circulation (the general indications for intubation hold good). Continuous monitoring of HR, SpO2, breathing pattern and Q15min-Q30min B.P checks are needed.

#### Investigations to be sent:

Complete blood count, bleeding/clotting time, PT/PTT, BUN, Se. creatinine, grouping and cross matching, SGOT/SGPT.

#### Indications for Anti Snake Venom (ASV)

Preferable administered within 4 hours of the bite. But can be given up to 96 hours of the bite.

# Severe local symptoms:

Rapid spread of the swelling, crossing a joint or involving half of the bitten limb, in the absence of a torniquet.

Development of enlarged, tender lymph nodes, draining the bitten limb.

# Systemic Envenomation

- Neurologic signs: Ptosis, external opthalmoplegia, altered sensorium, or seizures



- Cardiovascular abnormalities: Hypotension, shock, arrhythmias, abnormal ECG.

- Haemostatic abnormalities: Spontaneous bleeding manifestations, coagulopathy (>20 min whole blood clotting time or prolonged PT/PTT, thrombpcytopenia

- Acute renal failure, haemoglobinuria/myoglobinuria

- Respiratory distress, signs of upper airway obstruction.

- 8-10 vials of ASV are dissolved in 5-10ml/kg of isotonic fluid (150-300ml of NS or 5% Dextrose) and administered over 1-3 hours. If after 1-2 hours of administration, the child does not improve or worsens, a second and final dose should be given (max 25 vials).

Close monitoring for an anaphylactic reaction needs to be done. If any of these appears, ASV is discontinued and treatment for anaphylaxis (O2, fluid boluses, adrenaline 0.01mg/kg of 1;1000 solution IM, H1 and H2 blockers, IV steroids) started. Later ASV is restarted at a slower rate (of infusion) (1-2ml/kg/hr) and gradually increased.

#### Local wound management

The wound is cleaned thoroughly and left open. IV amoxicillin/clavulanate to be administered if the wound is open with severe local symptoms. Fasciotomy may be needed if there is evidence of compartment syndrome.



# CHAPTER-28 STATUS EPILEPTICS

• Status epilepticus is defined as a seizure with 5 minutes or more of continuous clinical and/or electrographic seizure activity or recurrent seizure activity without recovery between seizures.<sup>49</sup>

• International League Against Epilepsy definition of status epilepticus indicates that emergency treatment of status epilepticus should be started at t1 and long-term consequences may occur.<sup>50,51</sup>

Status Epilepticus Type	Time 1 (Treatment	Time 2 (Consequences
	Started)	Expected)
Tonic-clonic	5 min	30 min
Focal with impaired consciousness	10 min	>60 min
Absence	15 min	Unknown

• SE may also be an acute symptom of medical or neurologic disease. The more common examples of the latter includes<sup>49</sup>:

□ Central nervous system infections (e.g., meningitis, encephalitis, intracranial abscess)

- □ Acute hypoxic-ischemic insult
- □ Metabolic disease (e.g., hypoglycemia, inborn error of metabolism, hepatic encephalopathy)
- □ Electrolyte imbalance (hyponatremia, hypocalcemia.)
- □ Traumatic brain injury
- $\Box$  Drugs, intoxication, poisoning
- $\Box$  Cerebrovascular event

#### Management<sup>50</sup>:

Stabilization phase	Check and maintain ABC	
(Seizure 0 to 5 minutes)	<ul> <li>Give high flow oxygen</li> <li>Check blood glucose level</li> <li>Establish IV access and collect samples for electrolytes, calcium, haematological investigations and toxicology screen</li> </ul>	
Earlystatusepilepticus(Seizure5to30minutes)	<ul> <li>IV LORAZEPAM: 0.1mg/kg (max 4mg/dose) slowly over 2 to 5 minutes</li> <li>IV DIAZEPAM: 0.2mg/kg (max 10mg/dose) slowly over 2 to 5 minutes</li> </ul>	MIDAZOLAM 0.2mg/kg (max 5mg/dose)



Established status epilepticus (Seizure 30 to 60min)	<ul> <li>IM MIDAZOLAM 0.2mg/kg (max 10mg/dose)</li> <li>IV PHENYTOIN 20mg/kg (max 1000mg) infusion @ 1mg/kg/min with continuous cardiac monitoring</li> <li>IV LEVETIRACETAM 20 - 60mg/kg (max 4500mg) @ 5mg/kg/min</li> <li>IV SODIUM VALPROATE 20 - 40mg/kg (max 3000mg) @ 5mg/kg/min</li> <li>IV PHENOBARBITONE 20 - 40mg/kg (max 1000mg) @ 2mg/kg/min</li> </ul>	
Refractorystatusepilepticus(Seizure more than60min)	<ul> <li>RAPID SEQUENCE INTUBATION</li> <li>IV MIDAZOLAM 0.2mg/kg bolus F/B 1mcg/kg/min, increasing to 1 mcg/kg/min every 10 to 15 minutes up to maximum of 30mcg/kg/min</li> <li>HIGH DOSE PHENOBARBITONE COMA</li> <li>Others: INJ THIOPENTONE, SHORT TERM PROPOFOL, INJ KETAMINE</li> </ul>	
Super refractory	TOPIRAMATE	
status epilepticus	INHALED ANAESTHETICS	
(Seizure more than 24	Ketogenic diet	
hours)	Epilepsy surgery	
	Electroconvulsive therapy and deep brain stimulation	



# CHAPTER-29 TRICYCLIC ANTIDEPRESSANTS POISONING

TCA are used as antidepressants, anti –migraine medicine, and in treatment of attention deficit hyperactivity disorder, cyclical vomiting, neuropathic pain, and nocturnal enuresis and sleep disturbances.

E.g. Imipramine, Amitriptyline, Mapritiline, Amoxapine, Doxapane

#### Mechanism of toxicity

- □ Direct myocardial depression
- □ Anticholinergic effect
- □ Depletion of Norepinephrine

#### Symptoms

- $\Box$  CVS
- a. Dysrhythmia Sinus tachycardia, tosades, Ventricular tachycardia
- b. Condution delay
- c. Hypotension
- □ CNS Altered mental status, seizures
- □ Anti cholinergic toxicity Altered mental status, hyperthermia, urinary retention, and paralytic ileus.
- □ Pulmonary toxicity Acute lung injury.
- $\Box$  Acronym feature 3C & A Cardiac, coma, convulsion & acidosis.

#### Management

- □ Continuous ECG monitoring is mandatory.
- □ Support Airway, Breathing and Circulation

#### Gastric decontamination

Gastric lavage may be done upto 4 hours after ingestion, only after ensuring airway is protected.



#### Activated charcoal (AC)

# $\Box$ 1 g/kg

 $\hfill\square$  Multiple doses are indicated due to delayed gastric emptying.

# Symptomatic management

 $\Box$  In symptomatic / unstable patients at presentation or with rapid deterioration, support airway by early intubation

# Treat arrhythmias

 $\Box$  Mainstay of treatment – Sodium bicarbonate

□ Initial 1-2 meq/kg bolus followed by infusion Sodium bicarbonate containing solution as maintenance fluid (Sodium bicarbonate 150 meq/l in 5% Dextrose. Add potassium 20-40 meq/l of IV fluid) until arrhythmias are corrected & ORS duration < 100 ms.

 $\Box$  Goal is to maintain pH > 7.45, Severe intoxication pH; 7.5 – 7.55.

□ In arrhythmia unresponsive to Sodium bicarbonate, IV lignocaine or 3% NaCI can be considered.

# **Treatment of hypotension**

 $\Box$  NS bolus of 10 ml/kg – NS bolus to be administered cautiously due to concomitant myocardial depression, risk of pulmonary edema and acute lung injury.

 $\hfill\square$  Monitor for pulmonary edema.

□ If fluid unresponsive add vasopressors like Norepinephrine and Epinephrine to maintain BP.

# **Treatment of Seizures**

- $\Box$  Phenobarbitone to be used.
- $\Box$  Phenytoin is contra indicated.



# CHAPTER-30 TRAUMATIC BRAIN INJURY (TBI)

TBI is categorized by means of the Glasgow Coma Scale (GCS) as Severe: GCS  $\leq 8$ Moderate: GCS 9-13 Minor: GCS 14 and 15

# Minor Head Trauma:

The decision on imaging (Ct brain), observation in the ER, admission or discharge is based on the risk stratification.

# High Risk (CT recommended)

- □ Altered mental status
- $\Box$  Focal neurologic findings
- $\hfill\square$  Signs of depressed or basilar skull fracture by clinical examination
- □ Excessive irritability (inconsolable)
- □ Seizures
- $\Box$  Vomiting  $\geq$  5 episodes or  $\geq$  6 episodes per hour
- $\Box$  Loss of consciousness  $\geq 1$  minute

# Intermediate Risk (Observation and/or CT scan)

- $\Box$  Vomiting 3-4 episodes from time of injury.
- $\Box$  Loss of consciousness  $\leq 1$  minute
- □ H/o lethargy or irritability, now resolved
- $\hfill\square$  Behaviour not at baseline, reported by caretaker
- $\Box$  Non acute, skull fracture ( $\geq$  24 hours old)
- $\Box$  Frontal, parietotemporal, occipital swelling  $\geq$  3cm in younger children ( < 2 years)

# Low Risk (Recommend observation either in ER or at home)

- $\Box$  Low energy mechanisms (fall  $\leq$  3 feet)
- $\Box$  No signs or symptoms  $\geq 2$  hours since injury



#### Older age (especially $\geq 2$ years) is more reassuring.

Children with normal CT and/or normal examination can be discharged after 6 hours of observation. The possibility of delayed bleed should be emphasized and the family asked to return if any of the symptoms mentioned (vomiting, drowsiness/excessive irritability, seizures) appear.

#### Severe Traumatic Brain injury

The "Golden Hour" management is aimed at preventing and minimizing secondary insults to the brain. The initial priorities are management of the airway, breathing and circulation, simultaneously instituting measures to lower the ICP.

#### Airway and Breathing

Maintain 'C' spine immobilization at all times

Administer O2 by face mask and open airway by jaw thrust maneuver.

Intubate (by RSI) if:

 $\Box$  GCS < 8 or falls by more than two from the time of initial assessment.

- □ Hypoxic
- $\Box$  Respiratory efforts are poor.
- $\Box$  Protective airway reflexes are lost.

Drugs for intubation in the hemodynamically stable child:

Atropine (0.02 mg/Kg, max 1 mg)

- Lidocaine (1mg/Kg)
- Propofol (1-2 mg/Kg) or Midazolam (0.1 mg/Kg)
- Fentanyl  $(1-2 \mu g/Kg)$  and

Paralyze with Vecuronium (0.3 mg/Kg)

Use an orogastric tube to deflate the stomach.

Ventilate at rates appropriate for age (ETCO2 35-40 mm Hg)

Hyperventilate only if signs of impending herniation are present, which includes.

- $\Box$  Unequal pupils.
- □ Midpoint fixed/dilated pupils.
- □ Decorticate/decerebrate posturing.



□ Cheyne Stokes/irregular breathing /hyperventilation.

# Circulation

Obtain two large bore IV access

If  $B.P < 5^{th}$  centile, administer 20 ml/Kg of NS over 5 -10 min and repeat x 3 times till B. P improves.

Start dopamine +/- noradrenaline if B.P is low despite 3 fluid boluses. (Threshold for starting inotrops is low in TBI, to optimize Cerebral perfusion Pressure.

Consider blood loss in polytrauma victims and transfuse PRBC (20 ml/Kg)

# **ICP Lowering Measures**

Head end elevation to  $30^{\circ}$ 

Provide adequate analgesia/sedation.

Lidocaine 1mg/Kg before any painful procedure.

Seizure control as per status epilepticus protocol

Ventilate at rates appropriate for age.

Hyperventilate (ETCO2 35-40 mm Hg) only if signs of impending herniation are present.

Hyperosmolar therapy: Mannitol 1ml/Kg of 20% solution, in haemodynamically stable children,

3% Nacl 5ml/Kg in hemodynamically unstable children, followed by infusion of the same at 0.5-1 ml/Kg/hour.

# Shift the child for imaging only after airway, breathing and circulation are stabilized.



# BIBLIOGRAPHY

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023. Updated May 2023. Available from: www.ginasthma.org

2. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59-99.

3. Saharan, S., Lodha, R. & Kabra, S.K. Management of Status Asthmaticus in Children. Indian J Pediatr 77, 1417–1423 (2010). https://doi.org/10.1007/s12098-010-0189-8

4. Sethi GR, Bajaj M, Sehgal V. Management of acute asthma. Indian Pediatr. 1998 Aug;35(8):745-62. PMID: 10216568

5. Sampson HA, Muñoz-Furlong A, Campbell RL et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006 Feb;117(2):391-7.

6. Brown SGA, Kemp SF, Lieberman PL. Anaphylaxis. In: Middleton's Allergy: Principles and Practice, 8th edition, Adkinson NF Jr, Bochner BS, Burks AW, et al (Eds), Elsevier, Philadelphia 2014. p.1237.

7. Up-to-date

8. Suddock JT, Kent KJ, Cain MD. Barbiturate Toxicity. [Updated 2023 Apr 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499875/

9. Mactier R, Laliberté M, Mardini J, Ghannoum M, Lavergne V, Gosselin S, Hoffman RS, Nolin TD; EXTRIP Workgroup. Extracorporeal treatment for barbiturate poisoning: recommendations from the EXTRIP Workgroup. Am J Kidney Dis. 2014 Sep;64(3):347-58. doi: 10.1053/j.ajkd.2014.04.031. Epub 2014 Jul 3. PMID: 24998037.

10. Riordan M, Rylance G, Berry KPoisoning in children 1: General managementArchives of Disease in Childhood 2002;87:392-396.

11. American Academy of Pediatrics Subcommittee on D, Management of B. Diagnosis and management of bronchiolitis. Pediatrics. 2006;118:1774–1793. [PubMed] [Google Scholar] [Ref list]



12. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. Clinical practice guideline: the diagnosis, management and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474-502.

13. National Institute for Health and Care Excellence. (2015). Bronchiolitis in children: diagnosis and management. [online] Available from www.nice.org.uk/guidance/ng9. [Last accessed March, 2022].

14. Kumar S, Kavitha TK, Angurana SK. Kerosene, Camphor, and Naphthalene Poisoning in Children. Indian J Crit Care Med 2019;23(Suppl 4):S278–S281.

15. Manoguerra AS, Erdman AR, Wax PM, Nelson LS, Caravati EM, Cobaugh DJ, Chyka PA, Olson KR, Booze LL, Woolf AD, Keyes DC, Christianson G, Scharman EJ, Troutman WG; American Association of Poison Control Centers. Camphor Poisoning: an evidence-based practice guideline for out-of-hospital management. Clin Toxicol (Phila). 2006;44(4):357-70. doi: 10.1080/15563650600671696. PMID: 16809137.

16. Sahana KS, Rajiv D. Camphor poisoning. Indian Pediatr 2012;49(10):841-842. DOI: 10.1007/s13312-012-0174-6.

17. Up-to-date

18. Sarma MS, Tripathi PR, Arora S. Corrosive upper gastrointestinal strictures in children: Difficulties and dilemmas. World J Clin Pediatr. 2021 Nov 9;10(6):124-136. doi: 10.5409/wjcp.v10.i6.124. PMID: 34868889; PMCID: PMC8603639.

Jessica Retzke; Croup (Acute Laryngotracheobronchitis). Quick References 2021;
 10.1542/aap.ppcqr.396247

20. Smith DK, McDermott AJ, Sullivan JF. Croup: Diagnosis and Management. Am Fam Physician. 2018 May 1;97(9):575-580. PMID: 29763253.

21. Bjornson CL, Johnson DW. Croup in children. CMAJ. 2013;185(15):1317-1323

22. Up-to-date

23. Wilson R, Ross O, Griksaitis MJ. Tetralogy of Fallot. BJA Educ. 2019 Nov;19(11):362-369. doi: 10.1016/j.bjae.2019.07.003. Epub 2019 Oct 14. PMID: 33456859; PMCID: PMC7807827.

24. Up-to-date

25. Taksande A, Gautami V, Padhi S, Bakshi K. Hypercyanotic spells. J MGIMS 2009;14(ii):7–9

26. BSPED Interim Guideline for the Management of Children and Young People under the age of 18 years with Diabetic Ketoacidosis: January 2020



27. Dekate P, Jayashree M, Singhi SC. Management of acute diarrhea in emergency room. Indian J Pediatr. 2013 Mar;80(3):235-46. doi: 10.1007/s12098-012-0909-3. Epub 2012 Nov 30. PMID: 23192407.

28. Manual for the Health Care of Children in Humanitarian Emergencies. Geneva: World Health Organization; 2008. 3, Diarrhoea and dehydration. Available from: https://www.ncbi.nlm.nih.gov/books/NBK143745/

29. Mubarak A, Benninga MA, Broekaert I, Dolinsek J, Homan M, Mas E, Miele E, Pienar C, Thapar N, Thomson M, Tzivinikos C, de Ridder L. Diagnosis, Management, and Prevention of Button Battery Ingestion in Childhood: A European Society for Paediatric Gastroenterology Hepatology and Nutrition Position Paper. J Pediatr Gastroenterol Nutr. 2021 Jul 1;73(1):129-136. doi: 10.1097/MPG.000000000003048. PMID: 33555169.

30. Patel NH, Romero SK, Kaelber DC. Evaluation and management of pediatric hypertensive crises: hypertensive urgency and hypertensive emergencies. Open Access Emerg Med. 2012 Sep 5;4:85-92. doi: 10.2147/OAEM.S32809. PMID: 27147865; PMCID: PMC4753979.

31. Bertazza Partigiani N, Spagnol R, Di Michele L, Santini M, Grotto B, Sartori A, Zamperetti E, Nosadini M and Meneghesso D (2022) Management of Hypertensive Crises in Children: A Review of the Recent Literature. Front. Pediatr. 10:880678. doi: 10.3389/fped.2022.880678

32. Ferguson M, Stein D. Evaluation and treatment of hypertensive crises in children. Integr Blood Press Control. (2016) 9:49–58. doi: 10.2147/IBPC.S50640

33. Chhaya A Divecha, Milind S Tullu. Kerosene Poisoning in Children: A Review. Indian J Trauma Emerg Pediatr. 2020;12(1): 29–36

34. Kumar S, Kavitha TK, Angurana SK. Kerosene, Camphor, and Naphthalene Poisoning in Children. Indian J Crit Care Med 2019;23(Suppl 4):S278–S281.

35. Peter JV, Sudarsan TI, Moran JL. Clinical features of organophosphate poisoning: A review of different classification systems and approaches. Indian J Crit Care Med. 2014 Nov;18(11):735-45. doi: 10.4103/0972-5229.144017. PMID: 25425841; PMCID: PMC4238091.

36. Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet. 2008 Feb 16;371(9612):597-607. doi: 10.1016/S0140-6736(07)61202-1. PMID: 17706760; PMCID: PMC2493390.

37. Robb EL, Baker MB. Organophosphate Toxicity. [Updated 2023 Apr 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470430/



38. Jordan MR, Morrisonponce D. Naloxone. [Updated 2023 Apr 29]. In: StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441910/

39. Up-to-date

40. Mund ME, Quarcoo D, Gyo C, Brüggmann D, Groneberg DA. Paracetamol as a toxic substance for children: aspects of legislation in selected countries. J Occup Med Toxicol. 2015 Dec 10; 10:43. doi: 10.1186/s12995-015-0084-3. PMID: 26664414; PMCID: PMC4674926.

41. General principles in the management of poisoning. In: Handbook on Poisoning in Children, IJPP Series-6. 2013:135–40.

42. Up-to-date

43. Castaldo ET, Chari RS. Liver transplantation for acute hepatic failure. HPB (Oxford). 2006;8(1):29-34. doi: 10.1080/13651820500465741. PMID: 18333235; PMCID: PMC2131363.

44. Ramchandra AM, Chacko B, Victor PJ. Pyrethroid Poisoning. Indian J Crit Care Med. 2019 Dec;23(Suppl 4):S267-S271. doi: 10.5005/jp-journals-10071-23304. PMID: 32021002; PMCID: PMC6996658.

45. Bradberry SM, Cage SA, Proudfoot AT, Vale JA. Poisoning due to pyrethroids. Toxicol Rev. 2005;24(2):93-106. doi: 10.2165/00139709-200524020-00003. PMID: 16180929.

46. Mahadevan S, Rameshkumar R. Systemic manifestations in children with scorpion sting envenomation: how to manage? Indian J Pediatr. 2015 Jun;82(6):497-8. doi: 10.1007/s12098-015-1705-7. Epub 2015 Feb 18. PMID: 25689958

47. IAP standard treatment guidelines 2022; scorpion envenomation

48. Up-to-date

49. Wylie T, Sandhu DS, Murr N. Status Epilepticus. 2023 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 28613459.

50. Aulická Š. Current Management of Generalized Convulsive Status Epilepticus in Children. Children (Basel). 2022 Oct 20;9(10):1586. doi: 10.3390/children9101586. PMID: 36291522; PMCID: PMC9600522.

51. Trinka E., Cock H., Hesdorffer D., Rossetti A.O., Scheffer I.E., Shinnar S., Shorvon S., Lowenstein D.H. A definition and classification of status epilepticus—Report of the ilae task force on classification of status epilepticus. Epilepsia. 2015;56:1515–1523. doi: 10.1111/epi.13121.